-
Product Insights
NewNet Present Value Model: Longeveron Inc’s Lomecel-B
Empower your strategies with our Net Present Value Model: Longeveron Inc's Lomecel-B report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cefepime + Taniborbactam Hydrochloride) in Pyelonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cefepime + Taniborbactam Hydrochloride) in Pyelonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cefepime + Taniborbactam Hydrochloride) in Pyelonephritis Drug Details: Fixed dose...
-
Product Insights
Congenital Heart Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Congenital Heart Disease - Drugs In Development, 2023’, provides an overview of the Congenital Heart Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Congenital Heart Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lomecel-B in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lomecel-B in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lomecel-B in Alzheimer's Disease Drug Details: Lomecel-B is under development for the...
-
Product Insights
NewNet Present Value Model: Novo Nordisk AS’s LAI-287 + Semaglutide
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Chronic Lymphocytic Leukemia (CLL) Drug Details: Pirtobrutinib (Jaypirca) is an anti-neoplastic agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QR-0561 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QR-0561 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.QR-0561 in Idiopathic Pulmonary Fibrosis Drug Details: QR-0561 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lomecel-B in Ageing
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lomecel-B in AgeingDrug Details:Lomecel-B is under development for the treatment of ageing frailty, hypoplastic left heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Invimestrocel in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Invimestrocel in Traumatic Brain Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Invimestrocel in Traumatic Brain InjuryDrug Details:Invimestrocel (PF05285401) is under development for the...
-
Thematic Analysis
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...